Site Sponsors
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Strem Chemicals - Nanomaterials for R&D
  • Park Systems - Manufacturer of a complete range of AFM solutions
Posted in | Nanomedicine

There is 1 related live offer.

Save 25% on magneTherm

Dr. Fetzer to Highlight Nanopharmaceutical Advancement at BioPharm America Event

Published on September 17, 2010 at 5:08 AM

Cerulean Pharma Inc., a leader in nanopharmaceuticals, today announced that the Company’s chief executive, Oliver Fetzer, Ph.D., will present at the BioPharm America(TM) conference being held in Boston, Massasachusetts, from September 15-17, 2010.

The premier pharmaceutical partnership conference has joined forces with MassBio Investors Forum to bring together pharmaceutical industry executives and life science investors for one of the largest and most productive partnering events. Dr. Fetzer will brief attendees on Cerulean’s key accomplishments and positive momentum.

A key accomplishment that Dr. Fetzer will highlight is the Company’s initiation of a multi-site Phase 2a clinical study of its first-in-class nanopharmaceutical, CRLX101, in advanced cancer patients. Findings from Cerulean’s Phase 1 study with CRLX101 demonstrated clinical activity in several patients and a favorable safety profile. These data were presented at the recent 2010 American Chemical Society National Meeting & Exposition held last month in Boston, Massachusetts.

Dr. Fetzer will also describe the advancement of the Company’s lead pre-clinical candidate, CRLX288, a novel docetaxel nanopharmaceutical. Docetaxel is one of the most widely prescribed oncology drugs and is efficacious in many solid tumors. CRLX288 has been designed to further enhance the efficacy of docetaxel by maximizing drug exposure in cancer cells while at the same time minimizing bone marrow toxicity, neurotoxicity, and drug resistance, which are some of docetaxel’s clinical limitations.

“Cerulean is leading the industry with CRLX101’s progression as a first-in-class nanopharmaceutical into Phase 2a development, which speaks to the strength of our platform,” said Dr. Fetzer. “Last month we presented data showing that our nanoparticles are stable in the bloodstream, preferentially accumulate in target disease tissues, penetrate deeply in tumors, and are taken up by cancer cells. Cerulean’s nanopharmaceutical platform is unique in realizing these biological benefits, making it of keen interest to pharmaceutical companies and investors in cancer drug development, as well as in other therapeutic areas such as inflammation. We are excited about the progress Cerulean has made validating the nanopharmaceutical platform pre-clinically and increasingly in the clinic.”

Dr. Fetzer will present at 9:00 a.m. on Friday, September 17, in the Clarendon Room in Marriott Boston Copley, Boston, Massachusetts.

Source: http://www.ceruleanrx.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit